Latest Insider Transactions at Inhibrx, Inc. (INBX)
This section provides a real-time view of insider transactions for Inhibrx, Inc. (INBX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Inhibrx, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Inhibrx, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 30
2024
|
Viking Global Investors LP |
SELL
Other acquisition or disposition
|
Indirect |
7,150,826
-100.0%
|
$214,524,780
$30.0 P/Share
|
|
May 30
2024
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,055,553
-100.0%
|
$61,666,590
$30.0 P/Share
|
|
May 30
2024
|
Douglas Forsyth Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
598,257
-100.0%
|
$17,947,710
$30.0 P/Share
|
|
May 30
2024
|
Jon Faiz Kayyem Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,274,301
-100.0%
|
$98,229,030
$30.0 P/Share
|
|
May 30
2024
|
Mark Lappe Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,045,654
-100.0%
|
$91,369,620
$30.0 P/Share
|
|
May 28
2024
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
300,000
-14.74%
|
$10,200,000
$34.3 P/Share
|
|
Aug 28
2023
|
Viking Global Investors LP |
BUY
Open market or private purchase
|
Indirect |
511,627
+50.0%
|
$9,720,913
$19.35 P/Share
|
|
Mar 01
2023
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.96%
|
$960,000
$24.46 P/Share
|
|
Feb 28
2023
|
Mark Lappe Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
60
-0.0%
|
$1,500
$25.02 P/Share
|
|
Feb 02
2023
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
11,250
-0.27%
|
$281,250
$25.65 P/Share
|
|
Feb 01
2023
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
28,750
-0.45%
|
$718,750
$25.01 P/Share
|
|
Jan 24
2023
|
Mark Lappe Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
4,335
-0.09%
|
$108,375
$25.91 P/Share
|
|
Jan 23
2023
|
Mark Lappe Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
21,665
-0.86%
|
$541,625
$25.36 P/Share
|
|
Jan 23
2023
|
Jon Faiz Kayyem Director |
SELL
Open market or private sale
|
Indirect |
9,500
-0.29%
|
$237,500
$25.26 P/Share
|
|
Jan 04
2023
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
7,105
-0.17%
|
$163,415
$23.55 P/Share
|
|
Jan 03
2023
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
32,895
-0.51%
|
$789,480
$24.29 P/Share
|
|
Dec 21
2022
|
Jon Faiz Kayyem Director |
SELL
Open market or private sale
|
Indirect |
9,500
-0.15%
|
$256,500
$27.24 P/Share
|
|
Dec 19
2022
|
Mark Lappe Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
26,000
-0.51%
|
$650,000
$25.91 P/Share
|
|
Dec 06
2022
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.61%
|
$1,080,000
$27.62 P/Share
|
|
Nov 21
2022
|
Jon Faiz Kayyem Director |
SELL
Open market or private sale
|
Indirect |
9,500
-0.15%
|
$275,500
$29.73 P/Share
|
|
Nov 17
2022
|
Mark Lappe Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
26,000
-0.15%
|
$728,000
$28.78 P/Share
|
|
Nov 01
2022
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.9%
|
$1,320,000
$33.62 P/Share
|
|
Oct 21
2022
|
Jon Faiz Kayyem Director |
SELL
Open market or private sale
|
Indirect |
9,500
-0.15%
|
$275,500
$29.99 P/Share
|
|
Oct 17
2022
|
Mark Lappe Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
26,000
-0.25%
|
$780,000
$30.23 P/Share
|
|
Oct 07
2022
|
Viking Global Investors LP |
BUY
Open market or private purchase
|
Indirect |
1,333,333
+39.59%
|
$39,999,990
$30.0 P/Share
|
|
Oct 04
2022
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.25%
|
$1,080,000
$27.78 P/Share
|
|
Sep 13
2022
|
Brendan P. Eckelman Chief Scientific Officer |
BUY
Bona fide gift
|
Indirect |
160,000
+33.33%
|
-
|
|
Sep 13
2022
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Bona fide gift
|
Indirect |
160,000
-6.57%
|
-
|
|
Sep 06
2022
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.81%
|
$600,000
$15.26 P/Share
|
|
Aug 24
2022
|
Jon Faiz Kayyem Director |
SELL
Bona fide gift
|
Indirect |
11,900
-0.36%
|
-
|
|
Aug 05
2022
|
Jon Faiz Kayyem Director |
SELL
Bona fide gift
|
Indirect |
3,400
-0.1%
|
-
|
|
Aug 03
2022
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
15,500
-0.62%
|
$279,000
$18.47 P/Share
|
|
Aug 02
2022
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
24,500
-0.97%
|
$416,500
$17.7 P/Share
|
|
Aug 02
2022
|
Jon Faiz Kayyem Director |
BUY
Bona fide gift
|
Indirect |
50,000
+50.0%
|
-
|
|
Aug 02
2022
|
Jon Faiz Kayyem Director |
SELL
Bona fide gift
|
Indirect |
118,500
-3.49%
|
-
|
|
Jul 07
2022
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-1.57%
|
$680,000
$17.17 P/Share
|
|
Apr 05
2022
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
400
-0.02%
|
$10,000
$25.04 P/Share
|
|
Mar 24
2021
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
17,000
-0.66%
|
$323,000
$19.02 P/Share
|
|
Feb 17
2021
|
Klaus W. Wagner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
19,559
-8.33%
|
$488,975
$25.29 P/Share
|
|
Feb 16
2021
|
Klaus W. Wagner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
156,474
-40.0%
|
$3,755,376
$24.32 P/Share
|
|
Feb 16
2021
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
17,000
-0.66%
|
$425,000
$25.9 P/Share
|
|
Dec 28
2020
|
Mark Lappe Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
500,000
+50.0%
|
-
|
|
Dec 28
2020
|
Mark Lappe Chief Executive Officer |
SELL
Bona fide gift
|
Indirect |
500,000
-16.18%
|
-
|
|
Dec 04
2020
|
Brendan P. Eckelman Chief Scientific Officer |
BUY
Bona fide gift
|
Indirect |
160,000
+50.0%
|
-
|
|
Dec 04
2020
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Bona fide gift
|
Indirect |
160,000
-5.82%
|
-
|
|
Aug 26
2020
|
Viking Global Investors LP |
BUY
Open market or private purchase
|
Indirect |
180,219
+6.12%
|
$3,243,942
$18.92 P/Share
|
|
Aug 25
2020
|
Viking Global Investors LP |
BUY
Open market or private purchase
|
Indirect |
85,304
+3.3%
|
$1,620,776
$19.31 P/Share
|
|
Aug 24
2020
|
Viking Global Investors LP |
BUY
Open market or private purchase
|
Indirect |
46,161
+3.82%
|
$877,059
$19.43 P/Share
|
|
Aug 21
2020
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,129,003
+50.0%
|
-
|